



(51) International Patent Classification:

A61K 31/44 (2006.01) A61K 9/00 (2006.01)
A61K 31/573 (2006.01) A61P 27/02 (2006.01)
A61K 47/02 (2006.01)

(21) International Application Number:

PCT/US2024/039582

(22) International Filing Date:

25 July 2024 (25.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/528,674 25 July 2023 (25.07.2023) US


(71) Applicant: **IOLYX THERAPEUTICS, INC.** [US/US];
1325 Howard Ave, #904, Burlingame, California 94010
(US).

(72) Inventors: **JEFFORDS, Elizabeth W.**; 632 Fairway Circle, Hillsborough, California 94010 (US). **DAHL, Shannon L.M.**; 1455 Columbia Court, Palo Alto, California 94304 (US). **GRAHAM, Richard**; 5066 Balsawood, Irvine, California 92612 (US). **GUKASYAN, Hovhannes J.**; 7824 E San Luis Dr., Orange, California 92869 (US). **VERHOEVEN, Rozemarijn**; 245 Little Creek Lane, Siler City, North Carolina 27344 (US).

(74) Agent: **POSTAL, Brett A.** et al.; Rothwell, Figg, Ernst & Manbeck, P.C., 901 New York Ave., NW, Suite 900 East, Washington, District of Columbia 20001 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: OCULAR SURFACE TOPICAL ADMINISTRATION OF ROFLUMILAST FOR TREATMENT OF ANTERIOR AND RETINAL-VITREOUS CHAMBER OCULAR DISEASES



(57) Abstract: Methods of treating anterior or vitreous chamber ocular diseases by administering ophthalmic pharmaceutical compositions of roflumilast topically to the ocular surface of the eye of a patient. The methods involving topical administration of ophthalmic pharmaceutical compositions of roflumilast to the ocular surface of a patient three or four times a day at more frequent and higher concentration, which can provide significant therapeutic activity to the anterior and vitreous chamber compartments of the eye using dosing regimens involving higher concentrations and less frequent administration than other treatment regimens.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*